文献速递冠心病血脂与心血管预防

薄纤维帽粥样斑块预测FFR正常糖尿病患者的临床事件:COMBINE OCT-FFR试验

Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial.
PubMed 文献 · Eur Heart J · 2021-01-01

COMBINE OCT-FFR前瞻性双盲国际自然史研究纳入550例糖尿病患者,390例(81%)存在至少1处FFR阴性靶病变,其中98例(25%)为TCFA阳性。FFR阴性TCFA阳性组18个月主要终点发生率13.3%,显著高于TCFA阴性组的3.1%(HR 4.65;95%CI 1.99-10.89;P<0.001),多变量Cox回归显示TCFA是MACE最强预测因子(HR 5.12;95%CI 2.12-12.34;P<0.001)。

要点

  • FFR阴性糖尿病患者中25%存在TCFA,其18个月MACE风险约为TCFA阴性者的5倍。
  • TCFA是多变量分析中MACE最强预测因子(HR 5.12),独立于缺血评估。
  • 对FFR阴性但OCT检出TCFA的糖尿病患者,需重新评估风险分层策略。

核心结论

  • 在至少1处FFR阴性病变的糖尿病患者中,TCFA阳性者占25%,尽管无缺血证据,其MACE发生率仍高约5倍。
  • 易损斑块与缺血对未来不良事件影响的差异可能代表糖尿病患者冠脉疾病风险分层的范式转变。

研究设计与样本

  • COMBINE OCT-FFR为前瞻性、双盲、国际性自然史研究。
  • 共纳入550例患者,其中390例(81%)存在至少1处FFR阴性靶病变。
  • FFR阴性患者按是否存在至少1处TCFA病变分为TCFA阳性组(98例,25%)和TCFA阴性组(292例,75%)。

主要发现

  • 主要终点为18个月心源性死亡、靶血管心肌梗死、临床驱动的靶病变血运重建或需住院的不稳定心绞痛复合终点。
  • TCFA阳性组主要终点发生率为13.3%,TCFA阴性组为3.1%(HR 4.65;95%CI 1.99-10.89;P<0.001)。
  • 多变量Cox回归分析显示TCFA是MACE最强预测因子(HR 5.12;95%CI 2.12-12.34;P<0.001)。

关键数值与推荐

  • TCFA阳性定义为OCT检测到至少1处薄纤维帽粥样斑块。
  • FFR阴性病变定义为FFR评估后未行血运重建的靶病变。
  • 主要终点比较FFR阴性TCFA阳性与FFR阴性TCFA阴性患者18个月事件。

临床怎么用

  • 对糖尿病患者行FFR评估时,若FFR阴性但存在至少1处靶病变,可考虑OCT检测TCFA以识别高危人群。
  • FFR阴性但OCT检出TCFA的糖尿病患者可能需加强监测或个体化干预策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aim of this study was to understand the impact of optical coherence tomography (OCT)-detected thin-cap fibroatheroma (TCFA) on clinical outcomes of diabetes mellitus (DM) patients with fractional flow reserve (FFR)-negative lesions. METHODS AND RESULTS: COMBINE OCT-FFR study was a prospective, double-blind, international, natural history study. After FFR assessment, and revascularization of FFR-positive lesions, patients with ≥1 FFR-negative lesions (target lesions) were classified in two groups based on the presence or absence of ≥1 TCFA lesion. The primary endpoint compared FFR-negative TCFA-positive patients with FFR-negative TCFA-negative patients for a composite of cardiac mortality, target vessel myocardial infarction, clinically driven target lesion revascularization or unstable angina requiring hospitalization at 18 months. Among 550 patients enrolled, 390 (81%) patients had ≥1 FFR-negative lesions. Among FFR-negative patients, 98 (25%) were TCFA positive and 292 (75%) were TCFA negative. The incidence of the primary endpoint was 13.3% and 3.1% in TCFA-positive vs. TCFA-negative groups, respectively (hazard ratio 4.65; 95% confidence interval, 1.99-10.89; P < 0.001). The Cox regression multivariable analysis identified TCFA as the strongest predictor of major adverse clinical events (MACE) (hazard ratio 5.12; 95% confidence interval 2.12-12.34; P < 0.001). CONCLUSIONS: Among DM patients with ≥1 FFR-negative lesions, TCFA-positive patients represented 25% of this population and were associated with a five-fold higher rate of MACE despite the absence of ischaemia. This discrepancy between the impact of vulnerable plaque and ischaemia on future adverse events may represent a paradigm shift for coronary artery disease risk stratification in DM patients.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Kedhi E, Berta B, Roleder T, et al. Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT-FFR trial. Eur Heart J. 2021. PMID: 34345911. doi:10.1093/eurheartj/ehab433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。